Highlights of Recent Updates in Myeloma: Part 2 - R/R Treatment

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

July 31, 2024

Feat. C. Harrison

Houston Methodist

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

Indy Hematology Review

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

2024 ASCO® Annual Meeting Insights Hub

Dana-Farber Cancer Institute

Maria-Victoria Mateos

Springer Healthcare IME

SOHO Brazil 2024

Yale Cancer Center

University of Colorado Department of Medicine

Integrity CE

S. Usmani, J. Hillengass

MyCancerHaven

R. Vij, S. Al Hadidi

Insights from 2024 EHA Annual Meeting

S. Al Hadidi

Joseph Mikhael

2024 ASCO® Annual Meeting Insights Hub

Indy Hematology Review

Insights from 2023 ASH Annual Meeting

Login

Login

Join VuMedi

Highlights of Recent Updates in Myeloma: Part 2 - R/R Treatment

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Optimizing the Management of Patients with Polycythemia Vera (PV)

Related Videos

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Multiple Myeloma: Not as Simple as "CRAB" Anymore

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

ESMO 2024 Summary: Highlights in Heme Malignancies

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

Advances in Multiple Myeloma 2024: From Bench to Bedside

CARTITUDE-4 Update: OS With Cilta-Cel vs. SOC in Len-Refractory Mult…

Anti-BMCA Bispecific Antibodies - Independent Symposium at the 10th …

When to Consider Bispecific and CAR-T Therapy in MM

Multiple Myeloma: Hot Topics in 2024

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

Highlights in Plasma Cell Disorders From ASCO® and EHA

The Relapsed and Refractory MM Patient: When Immune Approaches Are I…

Indefinite Treatment of Multiple Myeloma: Strategies for Frail Patie…

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maintenanc…

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key Takeaways"

MRD Testing in Leukemias: When Negativity Is a Positive Thing